scholarly journals Effect of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in Children

2015 ◽  
Vol 62 (1) ◽  
pp. 131-132 ◽  
Author(s):  
Corinne Levy ◽  
Emmanuelle Varon ◽  
Stéphane Béchet ◽  
Robert Cohen
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Meningitis ◽  
Meningitis In Children

scholarly journals Pneumococcal Conjugate Vaccine Impact on Meningitis and Pneumonia Among Children Aged <5 Years—Zimbabwe, 2010–2016

2019 ◽  
Vol 69 (Supplement_2) ◽  
pp. S72-S80 ◽  
Author(s):  
Vongai Dondo ◽  
Hilda Mujuru ◽  
Kusum Nathoo ◽  
Vengai Jacha ◽  
Ottias Tapfumanei ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Meningitis ◽  
Negative Binomial ◽  
Negative Binomial Regression ◽  
Negative Binomial Regression Model ◽  
Pediatric Pneumonia ◽  
Vaccine Impact ◽  
Meningitis In Children ◽  
The Impact

Abstract Background Streptococcus pneumoniae is a leading cause of pneumonia and meningitis in children aged <5 years. Zimbabwe introduced 13-valent pneumococcal conjugate vaccine (PCV13) in 2012 using a 3-dose infant schedule with no booster dose or catch-up campaign. We evaluated the impact of PCV13 on pediatric pneumonia and meningitis. Methods We examined annual changes in the proportion of hospitalizations due to pneumonia and meningitis among children aged <5 years at Harare Central Hospital (HCH) pre-PCV13 (January 2010–June 2012) and post-PCV13 (July 2013–December 2016) using a negative binomial regression model, adjusting for seasonality. We also evaluated post-PCV13 changes in serotype distribution among children with confirmed pneumococcal meningitis at HCH and acute respiratory infection (ARI) trends using Ministry of Health outpatient data. Results Pneumonia hospitalizations among children aged <5 years steadily declined pre-PCV13; no significant change in annual decline was observed post-PCV13. Post-PCV13 introduction, meningitis hospitalization decreased 30% annually (95% confidence interval [CI], –42, –14) among children aged 12–59 months, and no change was observed among children aged 0–11 months. Pneumococcal meningitis caused by PCV13 serotypes decreased from 100% in 2011 to 50% in 2016. Annual severe and moderate outpatient ARI decreased by 30% (95% CI, –33, –26) and 7% (95% CI, –11, –2), respectively, post-PCV13 introduction. Conclusions We observed declines in pediatric meningitis hospitalizations, PCV13-type pneumococcal meningitis, and severe and moderate ARI outpatient visits post-PCV13 introduction. Low specificity of discharge codes, changes in referral patterns, and improvements in human immunodeficiency virus care may have contributed to the lack of additional declines in pneumonia hospitalizations post-PCV13 introduction.

scholarly journals Impact of 10-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children up to two years of age in Brazil

2015 ◽  
Vol 31 (2) ◽  
pp. 276-284 ◽  
Author(s):  
Indianara Maria Grando ◽  
Camile de Moraes ◽  
Brendan Flannery ◽  
Walter Massa Ramalho ◽  
Marco Aurélio P. Horta ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Meningitis ◽  
Incidence Rates ◽  
Morbidity And Mortality ◽  
Ecological Analysis ◽  
Post Vaccination ◽  
Meningitis In Children ◽  
Using Data ◽  
The Impact

The objective of this study was to analyze the impact of vaccination against Streptococcus pneumoniae on the morbidity and mortality from pneumococcal meningitis in children ≤ 2 years in Brazil, from 2007 to 2012. This is a descriptive study and ecological analysis using data from the Information System on Notifiable Diseases. Pre-vaccination (2007-2009) and post-vaccination (2011-2012) periods were defined to compare incidence rates and mortality. A total of 1,311 cases and 430 deaths were reported during the study period. Incidence decreased from 3.70/100,000 in 2007 to 1.84/100,000 in 2012, and mortality decreased from 1.30/100,000 to 0.40/100,000, or 50% and 69% respectively, with the greatest impact in the 6-11 month age group. This decrease in Pneumococcal meningitis morbidity and mortality rates two years after introduction of the 10-valent pneumococcal conjugate vaccine suggests its effectiveness.

Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children

Vaccine ◽  
2017 ◽  
Vol 35 (35) ◽  
pp. 4646-4651 ◽  
Author(s):  
Jesus Ruiz-Contreras ◽  
Juan Picazo ◽  
Juan Casado-Flores ◽  
Fernando Baquero-Artigao ◽  
Teresa Hernández-Sampelayo ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Meningitis ◽  
Meningitis In Children

Impact of the 13-valent pneumococcal conjugate vaccine on the incidence of pneumococcal meningitis in children

2015 ◽  
Vol 144 (3) ◽  
pp. 607-611 ◽  
Author(s):  
A. G. CHAPOUTOT ◽  
R. DESSEIN ◽  
O. GUILLUY ◽  
M. LAGRÉE ◽  
F. WALLET ◽  
...  
Keyword(s):  
Cohort Study ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Retrospective Cohort ◽  
Pneumococcal Meningitis ◽  
Northern France ◽  
Capture Recapture ◽  
Meningitis In Children ◽  
The Impact ◽  
Global Population

SUMMARYThe impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on the incidence of pneumococcal meningitis (PM) in children is unknown. To determine this impact, a descriptive multicentre retrospective cohort study was conducted from 2008 to 2013 in northern France. All laboratory-confirmed PM in children aged <18 years in all hospitals of the area with paediatric units were included. Two independent databases were used for exhaustive identification of cases: medical plus laboratory records at each hospital and discharge codes. The corrected incidence of PM was determined by a capture–recapture analysis using these two databases. Sixty-two cases were found over the 6-year period. A decrease of the PM corrected incidence was observed in the global population (P = 0·07), significant only for children aged <2 years, from 11·9/100 000 in 2008 in 1·9/100 000 in 2013 [6·4 fold-decrease, 95% confidence interval (CI) 1·4–41, P = 0·01] between years 2008 and 2013. When comparing the pre- and post-PCV13 periods, this decrease was still statistically significant for children aged <2 years [7·32/100 000 (95% CI 4·39–10·25) to 2·78/100 000 (95% CI 0·96–4·60), P = 0·01]. Only three (5%) cases of PM caused by vaccine serotypes could have been prevented. After the introduction of the PCV13 vaccine, a decrease in the incidence of PM cases in children in northern France was observed.

Trends of Pneumococcal Meningitis in Children After Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in France

2014 ◽  
Vol 33 (12) ◽  
pp. 1216-1221 ◽  
Author(s):  
Corinne Levy ◽  
Emmanuelle Varon ◽  
Capucine Picard ◽  
Stéphane Béchet ◽  
Alain Martinot ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Meningitis ◽  
Meningitis In Children

scholarly journals Use of 7-valent pneumococcal conjugate vaccine in EU

2006 ◽  
Vol 11 (49) ◽  
Author(s):  
P L Lopalco ◽  
Collective Editorial team
Keyword(s):  
Streptococcus Pneumoniae ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Meningitis ◽  
Invasive Disease ◽  
Morbidity And Mortality

Invasive disease due to Streptococcus pneumoniae is an important cause of morbidity and mortality in Europe as well as worldwide. Pneumococcal meningitis, septicaemia and pneumonia are particularly frequent in children

Sign in / Sign up

Export Citation Format

Share Document